Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study

Table 4 Change from baseline to endpoint for weight (safety set), n (%)

Measure		Lurasidone (40 mg/day), n = 99	Lurasidone (80 mg/day), n = 98
Weight, kg	Baseline, mean (SD)	64.98 (18.50)	61.04 (12.21)
	Mean change (SD)	0.83 (2.83)a	-0.08 (2.22)
	≥ 7% weight gain	12 (12.1)	4 (4.1)
	≥ 7% weight loss	3 (3.0)	4 (4.1)
BMI (kg/m2)	Baseline, mean (SD)	23.89 (5.87)	22.97 (4.30)
	Mean change (SD)	0.30 (1.06)a	-0.01 (0.86)
	≥ 7% BMI gain	12 (12.1)	4 (4.1)
	≥ 7% BMI loss	3 (3.0)	4 (4.1)

^aP < 0.01 vs baseline.

BMI: Body mass index.